Systemic safety analysis of mycophenolate in Graves ’ orbitopathy

ConclusionThe risk –benefit ratio of low-dose mycophenolate treatment in active moderate-to-severe GO is highly favorable given its reassuring safety profile with low rate of mild-to-moderate SE and promising efficacy.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research